Page 120 - TD-4-1

Tumor Discovery HHT inhibits pancreatic cancer progress

liver, and pancreas cancers in the United States. Cancer Res. of mutant p53: The mutant p53/NF-Y protein complex
2014;74(11):2913-2921. reveals an aberrant transcriptional mechanism of cell cycle
regulation. Cancer Cell. 2006;10(3):191-202.
doi: 10.1158/0008-5472.CAN-14-0155
doi: 10.1016/j.ccr.2006.08.013
24. Liu J, He X, Deng S, et al. QDPR deficiency drives
immune suppression in pancreatic cancer. Cell Metab. 34. Di Agostino S, Sorrentino G, Ingallina E, et al. YAP enhances
2024;36(5):984-999.e8. the pro-proliferative transcriptional activity of mutant p53
proteins. EMBO Rep. 2016;17(2):188-201.
doi: 10.1016/j.cmet.2024.03.015
doi: 10.15252/embr.201540488
25. Tintelnot J, Xu Y, Lesker TR, et al. Microbiota-derived 3-IAA
influences chemotherapy efficacy in pancreatic cancer. 35. Winters ZE, Ongkeko WM, Harris AL, Norbury CJ. p53
Nature. 2023;615(7950):168-174. regulates Cdc2 independently of inhibitory phosphorylation
to reinforce radiation-induced G2 arrest in human cells.
doi: 10.1038/s41586-023-05728-y Oncogene. 1998;17(6):673-684.
26. Zhang W, Gong M, Zhang W, et al. Thiostrepton induces doi: 10.1038/sj.onc.1201991
ferroptosis in pancreatic cancer cells through STAT3/GPX4
signalling. Cell Death Dis. 2022;13(7):630. 36. Le Gac G, Estève PO, Ferec C, Pradhan S. DNA damage-
induced down-regulation of human Cdc25C and Cdc2 is
doi: 10.1038/s41419-022-05082-3 mediated by cooperation between p53 and maintenance
27. Badgley MA, Kremer DM, Maurer HC, et al. Cysteine DNA (cytosine-5) methyltransferase 1. J Biol Chem.
depletion induces pancreatic tumor ferroptosis in mice. 2006;281(34):24161-24170.
Science. 2020;368(6486):85-89. doi: 10.1074/jbc.M603724200
doi: 10.1126/science.aaw9872 37. Thanasoula M, Escandell JM, Suwaki N, Tarsounas M.
28. Zhang J, Geng H, Liu L, Zhang H. Synergistic cytotoxicity ATM/ATR checkpoint activation downregulates CDC25C
of homoharringtonine and etoposide in acute myeloid to prevent mitotic entry with uncapped telomeres. EMBO J.
leukemia cells involves disrupted antioxidant defense. 2012;31(16):3398-3410.
Cancer Manag Res. 2019;11:1023-1032. doi: 10.1038/emboj.2012.191
doi: 10.2147/CMAR.S187597 38. Lin Y, Xu J, Lan H. Tumor-associated macrophages in
29. Chenghao H, Xuefeng L, Junli P, et al. Mitochondrial- tumor metastasis: Biological roles and clinical therapeutic
targeting strategies with homoharringtonine: A novel applications. J Hematol Oncol. 2019;12(1):76.
approach for chemoresistant rectal cancer. Biochem Biophys doi: 10.1186/s13045-019-0760-3
Res Commun. 2025;743:151141.
39. Wang Y, Johnson KCC, Gatti-Mays ME, Li Z. Emerging
doi: 10.1016/j.bbrc.2024.151141 strategies in targeting tumor-resident myeloid cells for
30. Nunnari J, Suomalainen A. Mitochondria: In sickness and in cancer immunotherapy. J Hematol Oncol. 2022;15(1):118.
health. Cell. 2012;148(6):1145-1159. doi: 10.1186/s13045-022-01335-y
doi: 10.1016/j.cell.2012.02.035 40. Plett R, Mellor P, Kendall S, et al. Homoharringtonine
demonstrates a cytotoxic effect against triple-negative breast
31. Bullock AN, Fersht AR. Rescuing the function of mutant
p53. Nat Rev Cancer. 2001;1(1):68-76. cancer cell lines and acts synergistically with paclitaxel. Sci
Rep. 2022;12(1):15663.
doi: 10.1038/35094077
doi: 10.1038/s41598-022-19621-7
32. Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C.
Gain-of-function mutant p53 but not p53 deletion promotes 41. Beranova L, Pombinho AR, Spegarova J, et al. The plant
alkaloid and anti-leukemia drug homoharringtonine
head and neck cancer progression in response to oncogenic sensitizes resistant human colorectal carcinoma cells
K-ras. J Pathol. 2011;225(4):479-489.
to TRAIL-induced apoptosis via multiple mechanisms.
doi: 10.1002/path.2971 Apoptosis. 2013;18(6):739-750.
33. Di Agostino S, Strano S, Emiliozzi V, et al. Gain of function doi: 10.1007/s10495-013-0823-9

Volume 4 Issue 1 (2025) 112 doi: 10.36922/td.7825